Search hospitals > Missouri > Chesterfield

Saint Luke's Hospital

Claim this profile
Chesterfield, Missouri 63017
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Lymphoma
141 reported clinical trials
3 medical researchers
Photo of Saint Luke's Hospital in ChesterfieldPhoto of Saint Luke's Hospital in ChesterfieldPhoto of Saint Luke's Hospital in Chesterfield

Summary

Saint Luke's Hospital is a medical facility located in Chesterfield, Missouri. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Breast cancer, Lymphoma and other specialties. Saint Luke's Hospital is involved with conducting 141 clinical trials across 307 conditions. There are 3 research doctors associated with this hospital, such as Joseph Sokhn, Mark J. Fesler, and Donald F. Busiek.

Area of expertise

1Skin Cancer
Global Leader
Saint Luke's Hospital has run 38 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Saint Luke's Hospital has run 37 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
Stage IV

Top PIs

Clinical Trials running at Saint Luke's Hospital

Breast Cancer
Lung Cancer
Lymphoma
Multiple Myeloma
Skin Cancer
Breast cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Heart Failure
Cancer
Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Recruiting1 award Phase 217 criteria
Image of trial facility.

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Luke's Hospital?
Saint Luke's Hospital is a medical facility located in Chesterfield, Missouri. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Breast cancer, Lymphoma and other specialties. Saint Luke's Hospital is involved with conducting 141 clinical trials across 307 conditions. There are 3 research doctors associated with this hospital, such as Joseph Sokhn, Mark J. Fesler, and Donald F. Busiek.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security